These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 18065810

  • 41. Comparative efficacy and safety of mycophenolate mofetil versus cyclophosphamide in patients with active antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of randomized trials.
    Song GG, Lee YH.
    Z Rheumatol; 2021 Jun; 80(5):425-431. PubMed ID: 32337635
    [Abstract] [Full Text] [Related]

  • 42. Serum antineutrophil cytoplasmic antibody positivity at the time of renal biopsy is associated with disease activity of lupus nephritis.
    Zhang J, Lian R, Chen Y, Wan J.
    Ren Fail; 2024 Dec; 46(2):2357743. PubMed ID: 38847502
    [Abstract] [Full Text] [Related]

  • 43. [Clinical and pathological characterization of antineutrophil cytoplasmic antibody associated small vasculitis in children].
    Zhou JH, Tang JH, Shi H, Liu TL, Qiu LR, Chen Y.
    Zhonghua Er Ke Za Zhi; 2004 Jun; 42(6):408-11. PubMed ID: 15265421
    [Abstract] [Full Text] [Related]

  • 44. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study.
    Walsh M, Solomons N, Lisk L, Jayne DR.
    Am J Kidney Dis; 2013 May; 61(5):710-5. PubMed ID: 23375819
    [Abstract] [Full Text] [Related]

  • 45. Pauci-immune renal vasculitis: natural history, prognostic factors, and impact of therapy.
    Cohen BA, Clark WF.
    Am J Kidney Dis; 2000 Nov; 36(5):914-24. PubMed ID: 11054347
    [Abstract] [Full Text] [Related]

  • 46. Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis.
    Gregersen JW, Kristensen T, Krag SR, Birn H, Ivarsen P.
    Clin Exp Rheumatol; 2012 Nov; 30(1 Suppl 70):S39-47. PubMed ID: 22510451
    [Abstract] [Full Text] [Related]

  • 47. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis.
    Berti A, Alsawas M, Jawaid T, Prokop LJ, Lee JM, Jeong GH, Quintana LF, Moiseev S, Vaglio A, Tesar V, Geetha D, Shin JIL, Kronbichler A.
    Nephrol Dial Transplant; 2022 Oct 19; 37(11):2190-2200. PubMed ID: 34910216
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S, Hruskova Z, Segelmark M, Morgan MD, Hogan J, Lee SK, Dale J, Harper L, Tesar V, Jayne DR, Geetha D.
    Am J Nephrol; 2015 Oct 19; 41(4-5):296-301. PubMed ID: 26044574
    [Abstract] [Full Text] [Related]

  • 50. ANCA-associated vasculitis with renal involvement: an outcome analysis.
    Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD.
    Nephrol Dial Transplant; 2004 Jun 19; 19(6):1403-11. PubMed ID: 15069175
    [Abstract] [Full Text] [Related]

  • 51. Successful renal transplantation in a patient with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis: effect of early plasma exchange and mycophenolate mofetil.
    Sun Q, Cheng D, Wen J, Chen J, Gong D, Liu Z, Li L.
    Transplant Proc; 2008 Dec 19; 40(10):3764-6. PubMed ID: 19100484
    [Abstract] [Full Text] [Related]

  • 52. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.
    Brijker F, Magee CC, Tervaert JW, O'Neill S, Walshe JJ.
    Clin Nephrol; 1999 Dec 19; 52(6):344-51. PubMed ID: 10604641
    [Abstract] [Full Text] [Related]

  • 53. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA.
    Rheumatology (Oxford); 2006 Jun 19; 45(6):724-9. PubMed ID: 16399845
    [Abstract] [Full Text] [Related]

  • 54. [Rapidly progressive glomerulonephritis in ANCA-associated vasculitis: a course, treatment efficacy, prognosis].
    Tomilina NA, Biriukova LS, Egorova ET, Sukhanov AV, Stoliarevich ES, Kupavtseva OA, Fedorova ND, Frolov AV, Trushkin RN, Kurenkova LG.
    Ter Arkh; 2008 Jun 19; 80(6):15-24. PubMed ID: 18655470
    [Abstract] [Full Text] [Related]

  • 55. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement.
    Rihova Z, Jancova E, Merta M, Rysava R, Reiterova J, Zabka J, Tesar V.
    Kidney Blood Press Res; 2005 Jun 19; 28(3):144-52. PubMed ID: 15908752
    [Abstract] [Full Text] [Related]

  • 56. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H, Lee SM, Manno RL, Seo P, Geetha D.
    Semin Arthritis Rheum; 2015 Aug 19; 45(1):67-9. PubMed ID: 25796088
    [Abstract] [Full Text] [Related]

  • 57. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides.
    Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M.
    Arthritis Res Ther; 2005 Aug 19; 7(5):R1072-81. PubMed ID: 16207324
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.